NASDAQ:ORMP Oramed Pharmaceuticals (ORMP) Stock Price, News & Analysis $4.33 +0.13 (+3.10%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$4.33 0.00 (-0.02%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Oramed Pharmaceuticals Stock (NASDAQ:ORMP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Oramed Pharmaceuticals alerts:Sign Up Key Stats Today's Range$4.15▼$4.3450-Day Range$4.20▼$5.3452-Week Range$2.09▼$5.47Volume193,501 shsAverage Volume175,018 shsMarket Capitalization$180.13 millionP/E Ratio1.05Dividend Yield5.77%Price TargetN/AConsensus RatingHold Company Overview Oramed Pharmaceuticals Inc. is a biopharmaceutical company focused on developing oral delivery technologies for biologic drugs, including proteins and peptides that are traditionally administered by injection. Its technology is designed to protect these therapies as they pass through the gastrointestinal tract and facilitate absorption into the bloodstream. The company’s lead programs have included ORMD-0801, an oral insulin candidate developed for the treatment of diabetes, and oral formulations of other peptide-based therapies. Oramed has evaluated its candidates in clinical studies involving patients with diabetes and has also pursued partnerships and licensing opportunities to advance its oral drug-delivery platform. Founded in 2006, Oramed is headquartered in Jerusalem, Israel, and has maintained corporate operations in the United States. Nadav Kidron has served as the company’s chief executive officer, while Professor Miriam Kidron, one of the company’s founders, has been associated with its scientific leadership. The company’s shares trade on the Nasdaq Capital Market under the symbol ORMP.AI Generated. May Contain Errors. Read More Oramed Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreORMP MarketRank™: Oramed Pharmaceuticals scored higher than 41% of companies evaluated by MarketBeat, and ranked 693rd out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.2 / 5Analyst RatingHold Consensus RatingOramed Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageOramed Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Oramed Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Oramed Pharmaceuticals is 1.05, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.06.Price to Earnings Ratio vs. SectorThe P/E ratio of Oramed Pharmaceuticals is 1.05, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.30.Price to Book Value per Share RatioOramed Pharmaceuticals has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Oramed Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.35% of the float of Oramed Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverOramed Pharmaceuticals has a short interest ratio ("days to cover") of 7.33.Change versus previous monthShort interest in Oramed Pharmaceuticals has recently increased by 9.61%, indicating that investor sentiment is decreasing significantly. Dividend2.5 / 5Dividend StrengthModerate Dividend LeadershipOramed Pharmaceuticals is a leading dividend payer. It pays a dividend yield of 5.95%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthOramed Pharmaceuticals does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Oramed Pharmaceuticals is 6.07%. This payout ratio is at a healthy, sustainable level, below 75%.Read more about Oramed Pharmaceuticals' dividend. News and Social Media3.0 / 5News Sentiment0.85 News SentimentOramed Pharmaceuticals has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Oramed Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for ORMP on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Oramed Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $225,500.00 in company stock.Percentage Held by Insiders20.77% of the stock of Oramed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions12.73% of the stock of Oramed Pharmaceuticals is held by institutions.Read more about Oramed Pharmaceuticals' insider trading history. Receive ORMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ORMP Stock News HeadlinesFinancial Contrast: Recursion Pharmaceuticals (NASDAQ:RXRX) vs. Oramed Pharmaceuticals (NASDAQ:ORMP)October 8 at 4:15 AM | americanbankingnews.comOramed Pharmaceuticals (NASDAQ:ORMP) COO Joshua Hexter Sells 30,000 Shares of StockOctober 3, 2026 | americanbankingnews.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's visibility into consumer bank transactions. A pilot program is reportedly already underway, with wider rollout at major banks possibly beginning this summer. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what the document says and what steps account holders might consider.October 10 at 1:00 AM | Weiss Ratings (Ad)Oramed Pharmaceuticals (NASDAQ:ORMP) CFO Avraham Gabay Sells 20,000 Shares of StockOctober 3, 2026 | insidertrades.comOramed Pharmaceuticals consensus price target increased 12.00% to $7.14September 15, 2026 | msn.comOramed: Q2 Earnings SnapshotAugust 11, 2026 | chron.comOramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance SheetJune 25, 2026 | prnewswire.comORMP: View inclusion in Russell indexes as positive that could raise awareness in investment communityJune 18, 2026 | msn.comSee More Headlines ORMP Stock Analysis - Frequently Asked Questions How have ORMP shares performed this year? Oramed Pharmaceuticals' stock was trading at $2.85 at the start of the year. Since then, ORMP stock has increased by 51.9% and is now trading at $4.33. How were Oramed Pharmaceuticals' earnings last quarter? Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) announced its quarterly earnings results on Monday, August, 10th. The biotechnology company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.43 by $0.52. How do I buy shares of Oramed Pharmaceuticals? Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Oramed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oramed Pharmaceuticals investors own include TransEnterix (TRXDW), Compugen (CGEN), Sarepta Therapeutics (SRPT), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD) and Gilead Sciences (GILD). Company Calendar Last Earnings8/10/2026Today10/10/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (9m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ORMP's financial health is in the Green zone, according to TradeSmith. ORMP has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ORMP CIK1176309 Webwww.oramed.com Phone(844) 967-2633Fax972-2566-0004Employees13Year Founded2006Profitability EPS (Trailing Twelve Months)$4.12 Trailing P/E Ratio1.05 Forward P/E Ratio2.95 P/E GrowthN/ANet Income$64.05 million Net MarginsN/A Pretax MarginN/A Return on Equity-5.17% Return on Assets-4.54% Debt Debt-to-Equity RatioN/A Current Ratio4.98 Quick Ratio4.98 Sales & Book Value Annual Sales$2 million Price / Sales90.06 Cash Flow$0.09 per share Price / Cash Flow47.73 Book Value$5.02 per share Price / Book0.86Miscellaneous Outstanding Shares41,600,000Free Float32,957,000Market Cap$180.13 million OptionableOptionable Beta1.29 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:ORMP) was last updated on 10/10/2026 by MarketBeat.com Staff. From Our PartnersThis high yielding “gold annuity” is starting to move…Garrett Goggin, a 20+ year gold analyst, has called major moves before: Montage Gold up 2,567%, G2 Goldfields ...Golden Portfolio | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...TradeWins | SponsoredNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...Eagle Publishing | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
